TENNOR THERAP-B

6872
68.6001.44% ( -1.000 )
Delay Closed: Nov 16, 16:08:11

Overview

TENNOR THERAP-B (6872)

TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial...

Open
75.650
High
75.950
Low
67.500
Prev. Close
69.600
Volume
19.90K
Turnover
1.39M
Avg Price
70.058
Bid/Ask Ratio
-66.67%
Amplitude
12.14%
52wk High
287.000
Volume Ratio
0.40
Turnover Ratio
0.04%
52wk Low
62.250
HK Mkt Cap
3.38B
Market CapHKD
3.59B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-3.07
EPSDynamic
-2.83
EPSStatic
--
BVPS
14.42
P/B
4.76
HK Shares
49.22M
Dividend YieldTTM
--
DividendTTM
--
Shares
52.30M
Min lot size
50
Currency
HKD

Daily Events

  1. Nov, 16

    Tennor Therapeutics-B reversed early gains today, opening at HK$75.65 before sliding to HK$67.50 by 10:04 BJ and closing at HK$68.60, down 1.4% from HK$69.60, as the lift from the first Phase IIb patient enrollment for rifaquizinone in prosthetic joint infection and a buyback mandate of up to RMB50 million faded in thin trading; turnover was only HK$1.39 million and turnover rate 0.040%. Q2 EPS was a loss of HK$0.8585 and net loss HK$37.10 million, narrowing 13.37% year on year, while operating loss widened 47.12%, keeping the clinical-stage investment profile intact. The stock is down 67.49% year to date, 76.1% below its 52-week high of HK$287, just 10.2% above its 52-week low of HK$62.25, and below MA20 of HK$78.20 and MA60 of HK$119.03. Still, the buyback and clinical progress offer some support.

  2. Nov, 13

    TenNor Therapeutics (6872.HK) spiked and faded, closing at HK$69.60, down 2.11%, after an early probe to HK$72.00 met no follow-through buying and the afternoon slid to HK$67.25 before a late repair; turnover was just 39,750 shares worth HK$2.75 million, a 0.08% turnover rate, so existing buyback and incentive news no longer moved a thin tape. Incremental flow was limited to the board-approved H-share buyback of up to RMB 50 million and the related next-day disclosure return, plus shareholder approval of the 2026 H-share award scheme, while first-patient enrolment in the Phase IIb rifaquizinone trial for prosthetic joint infection was already digested. Fundamentals remain loss-making: Q2 2026 EPS was -HK$0.8585 with a net loss of HK$37.1 million, narrowing 13.37% year on year, while operating loss widened 47.12%. The stock is down 67.01% year to date, 75.75% below its June 23 high of HK$287 and only 11.81% above its November 2 low of HK$62.25, and sits well under its MA20 of HK$79.85. Though at 4.83x PB and HK$3.64 billion market value, the very thin volume leaves it prone to outsized swings.

  3. Nov, 10

    Tennor Therapeutics-B closed at HK$71.50, up 1.85% from HK$70.20, in a spike-and-fade session: an early 09:35 high of HK$73.60 gave way to HK$69.10 by 10:08, with the afternoon recovering to HK$71.70 on thin volume of 30,100 shares. Support comes from steady buybacks — 25,200 shares repurchased across the four sessions from Oct 27 to Nov 5 for about HK$2.0 million — alongside first-patient enrollment in the Phase IIb trial of TNP-2092 intra-articular injection for prosthetic joint infection. Fundamentals remain loss-making: Q2 2026 EPS of -HK$0.8585, a net loss of HK$37.1 million, and an operating loss widening 47.12% year on year with ROE at -19.62%. The stock sits 14.86% above its Nov 2 52-week low of HK$62.25 but below MA20 of HK$84.88 and MA60 of HK$127.15, down 66.11% year to date and 75.09% below the June 23 high of HK$287. However, single-session turnover is extremely thin, limiting the signal value of the tape.

  4. Nov, 9

    Tennor Therapeutics-B rose 6.36% to HK$70.20 from a HK$66.00 prior close, opening lower, spiking to HK$71.80 at 10:29 BJ and then fading through the afternoon session, on thin volume of 55,050 shares worth HK$3.83mn. Buybacks and pipeline news supplied the catalysts: the company spent HK$322,000, HK$340,500 and HK$280,900 on 5,000, 5,000 and 4,000 shares on 3-5 November, while TNP-2092 has selected intra-articular injection for prosthetic joint infection as its priority indication and the first patient has been enrolled in the Phase IIb trial. Fundamentals remain pre-revenue: Q2 EPS was -HK$0.8585 and the net loss of HK$37.1mn narrowed 13.37% year on year, yet the operating loss of HK$35.5mn widened 47.12%, with ROE at -19.62%. The stock is down 66.73% year to date, 75.54% below its 23 June 52-week high of HK$287, and still sits under its MA20 of HK$86.45 and MA60 of HK$129.28, only 12.77% above the 2 November low of HK$62.25. Though turnover of 0.11% and buybacks small against a HK$3.67bn market value suggest the move is a thin-liquidity impulse rather than a trend.

  5. Nov, 6

    Tennor Therap-B fell 5.71% to HK$66.00 in a spike-and-fade session: it opened flat at HK$70.00, slid to an intraday low of HK$65.45 at 13:01 BJ and closed near the day's trough on turnover of just 38,900 shares (about HK$2.6 million) and a 0.08% turnover rate, thin liquidity amplifying the move. The retreat extends the digestion of the late-October catalyst, first patient dosing in the Phase IIb trial of TNP-2092 intra-articular injection for prosthetic joint infection, which had lifted the stock more than 10% in a single session before two straight drops of 13% and 6%. Buybacks of 5,000, 5,000 and 4,000 shares on Nov 3-5, roughly HK$943,000 combined, were too small to support the price. Fundamentals remain loss-making: Q2 EPS -HK$0.8585 and a net loss of HK$37.1 million, narrowed 13.37% year on year, while the operating loss widened 47.12%. At HK$66.00 the shares sit 77% below the 52-week high of HK$287, down 68.72% YTD, below the MA20 of 88.24 and MA60 of 131.43, at 4.58x book, and only 6% above the 52-week low of HK$62.25, though the repeated buybacks still absorb some supply.

News